Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS3AP19 (Ribosomal protein S3A pseudogene 19) is classified as a pseudogene and does not encode a functional protein[5]. Pseudogenes arise from protein-coding genes but have lost their protein-coding ability due to mutations or lack of regulatory elements, and are generally not transcribed or translated into functional products. RPS3AP19 is one of multiple processed pseudogenes related to the RPS3A gene, which codes for a component of the small (40S) ribosomal subunit important in protein synthesis[1][3][5]. There is currently no evidence implicating RPS3AP19 itself in any biological function, disease process, or as a drug target. Its nomenclature, sequence similarity, and alias names all derive from its relationship to the parent RPS3A gene but, as a processed pseudogene, it is not considered therapeutically actionable[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein S3A pseudogene 19 (RPS3AP19).